Novel CCR1 antagonists with improved metabolic stability

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2175-2179

  Brown, Matthew F ^a   Avery, Mike ^a   Brissette, William H ^a   Chang, J H ^a   Colizza, Kevin ^a   Conklyn, Maryrose ^a   DiRico, Amy P ^a   Gladue, Ronald P ^a   Kath, John C ^a   Krueger, Suzanne S ^a   Lira, Paul D ^a   Lillie, Brett M ^a   Lundquist, Greg D ^a   Mairs, Erin N ^a   McElroy, Eric B ^a   McGlynn, Molly A ^a   Paradis, Timothy J ^a   Poss, Christopher S ^a   Rossulek, Michelle I ^a   Shepard, Richard M ^a   Sims, Jeff ^a   Strelevitz, Timothy J ^a   Truesdell, Susan ^a   Tylaska, Laurie A ^a   Yoon, Kwansik ^a   Zheng, Deye ^a   more..

^a PFIZER INC   (United States)

Author keywords

CCR1; Chemokine; Microsome

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; MONKEY; NONHUMAN; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; DOGS; HAPLORHINI; PHARMACOKINETICS; RECEPTORS, CHEMOKINE;

EID: 11144355807     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.022     Document Type: Article

References (16)

1. Proudfoot A.E.I. Nat. Rev. Immunol. 2:2002;106.
2. Gerard C., Rollins B.J. Nat. Immunol. 2:2001;108.
3. Luster A.D. New. Eng. J. Med. 338:1998;436.
4. Saeki T., Naya A. Curr. Pharm. Des. 9:2003;1201.
5. Horuk R. Methods. 29:2003;369.
6. Kath J.C., Dirico A.P., Gladue R.P., Martin W.H., McElroy E.B., Stock I.A., Tylaska L.A., Zheng D. Bioorg. Med. Chem. Lett. 2004;. preceding manuscript #1. doi:10.1016/j.bmcl.2004.02.020.
7. Kath J.C., Brissette W.H., Brown M.F., Conklyn M., DiRico A.P., Dorff P., Gladue R.P., Lillie B.M., Lira P.D., Mairs E.N., Martin W.H., McElroy E.B., McGlynn M.A., Paradis T.J., Poss C.S., Stock I.A., Tylaska L.A., Zheng D. Bioorg. Med. Chem. Lett. 2004;. preceding manuscript #2. doi:10.1016/j.bmcl. 2004.02.021.
8. Neote K., DeGregorio D., Mak J.Y., Horuk R., Schall T.J. Cell. 72:1993;415.
9. Cole K., Strick C., Paradis T., Ogborne K.T., Loetscher M., Gladue R.P., Lin W., Boyd J.G., Moser B., Wood D.E., Sahagan B.G., Neote K. J. Exp. Med. 187:1998;2009.
10. Obach R.S. Curr. Opin. Drug Discov. Dev. 4:2001;36.
11. As determined by mass spectral analysis.
12. 1H NMR and mass spectral data was used to assign the structure.
13. Calculated with ClogP version 4.0 from BioByte.
14. Glucuronidation would not have been detectable in vitro in liver microsomes under the experimental conditions employed.
15. Conklyn M.J., Neote K., Showell H.J. Cytokine. 8:1996;762.
16. Gladue R.P., Tylaska L.A., Brissette W.H., Lira P.D., Kath J.C., Poss C.S., Brown M.F., Paradis T.J., Conklyn M.J., Ogborne K.T., McGlynn M.A., Lillie B.M., DiRico A.P., Mairs E.N., McElroy E.B., Martin W.H., Stock I.A., Shepard R.M., Showell H.J., Neote K.S. J. Biol. Chem. 278:2003;40473.